TG Therapeutics, Inc.
TGTXNasdaqCIK 1001316HealthcareFiscal year ends Dec 31
Reports and events: 312 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-08-0517:01 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001437749-26-025955 |
| 2026-08-0307:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-025304 |
| 2026-06-1216:32 ET | 8-K | 5.07 Shareholder vote results | 0001437749-26-020491 |
| 2026-06-0307:34 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-019262 |
| 2026-05-2716:34 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-018586 |
| 2026-05-0617:00 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001437749-26-015246 |
| 2026-05-0607:25 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-015013 |
| 2026-04-3016:31 ET | DEF 14A | Proxy statementPeriod 2026-06-11 | 0001437749-26-014233 |
| 2026-03-2016:33 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001437749-26-009253 |
| 2026-02-2717:05 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001437749-26-006133 |
| 2026-02-2607:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-005733 |
| 2026-01-1316:27 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-001194 |
| 2025-11-0516:31 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001437749-25-033363 |
| 2025-11-0307:34 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-25-032658 |
| 2025-08-0816:38 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001437749-25-025745 |
| 2025-08-0407:35 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-25-024480 |
| 2025-06-1316:53 ET | 8-K | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001437749-25-020335 |
| 2025-05-0916:31 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001437749-25-015804 |
| 2025-05-0507:31 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-25-014402 |
| 2025-04-3016:18 ET | DEF 14A | Proxy statementPeriod 2025-06-12 | 0001437749-25-013860 |
| 2025-03-0316:02 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001437749-25-005908 |
| 2025-03-0307:19 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-25-005802 |
| 2025-01-1416:02 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-25-001106 |
| 2024-11-0716:33 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001437749-24-033948 |
| 2024-11-0407:19 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-24-033055 |
| 2024-08-0916:03 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001437749-24-025853 |
| 2024-08-0916:01 ET | 10-K/A | Annual report, amendedPeriod 2023-12-31 | 0001437749-24-025850 |
| 2024-08-0607:08 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-24-024718 |
| 2024-06-1716:48 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001437749-24-020510 |
| 2024-05-0616:59 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001437749-24-014849 |
| 2024-05-0107:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-24-014062 |
| 2024-04-2916:32 ET | DEF 14A | Proxy statementPeriod 2024-06-14 | 0001437749-24-013719 |
| 2024-02-2917:23 ET | 10-K | Annual reportPeriod 2023-12-31 | 0001437749-24-006144 |
| 2024-02-2807:24 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-24-005802 |
| 2024-01-1007:37 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-24-001061 |
| 2023-11-0617:01 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0001437749-23-030412 |
| 2023-11-0107:33 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-23-029660 |
| 2023-08-0416:30 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0001558370-23-013429 |
| 2023-08-0107:29 ET | 8-K | 1.01 Entry into a material agreement; 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001558370-23-012631 |
| 2023-06-1516:30 ET | 8-K | 5.07 Shareholder vote results | 0001558370-23-011140 |
| 2023-05-0807:59 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0001558370-23-008385 |
| 2023-05-0116:17 ET | DEF 14A | Proxy statement | 0001558370-23-007490 |
| 2023-05-0107:35 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001558370-23-007393 |
| 2023-03-0117:21 ET | 10-K | Annual reportPeriod 2022-12-31 | 0001558370-23-002610 |
| 2023-02-2807:33 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001558370-23-002239 |
| 2022-12-2816:30 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001558370-22-019019 |
| 2022-11-1007:38 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001558370-22-017292 |
| 2022-11-0916:30 ET | 10-Q | Quarterly reportPeriod 2022-09-30 | 0001558370-22-017180 |
| 2022-08-0916:01 ET | 10-Q | Quarterly reportPeriod 2022-06-30 | 0001558370-22-012854 |
| 2022-08-0807:37 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001558370-22-012517 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:01 ET. Listed shows no prices and gives no investment advice.